Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
SPM-2551 demonstrated robust and durable pharmacological activity following a single low-dose administration in preclinical Duchenne muscular dystrophy (DMD) models Data support Sapreme’s proprietary SPT platform, designed to overcome endosomal entrapment and enable intracellular delivery of RNA therapeutics “We believe these data are unprecedented in the field, showing superior efficacy after only a single, low dose, […]
